Merck(US:MRK) Xin Hua Cai Jing·2025-11-05 02:39Core Insights - Merck, a global leader in biopharmaceuticals, has showcased its medical innovations and collaborations with local pharmaceutical companies at the 8th China International Import Expo (CIIE) for the seventh consecutive year [1][2] - The company has introduced approximately 30 approved drugs and vaccines in China, covering areas such as oncology, anti-infection, diabetes, and rare diseases, including several innovative drugs making their debut at the expo [1] - Merck plans to introduce over 40 new products and indications to China in the next five years, focusing on breakthrough scientific achievements in various therapeutic areas [1][2] Drug and Vaccine Development - Merck's four-valent and nine-valent HPV vaccines have protected over 50 million women in China and have recently been approved for male use to prevent HPV-related cancers and diseases [2] - In the oncology sector, Merck has a product line centered on tumor immunotherapy, with 32 indications expected to be approved in China by August 2025, targeting high-mortality and difficult-to-treat cancers [2] Collaborations and Innovations - Over the past three years, Merck has engaged in multiple R&D collaborations with five local pharmaceutical companies, including Kelun-Biotech and Hengrui Medicine, focusing on cardiovascular, metabolic, and oncology fields [2] - The establishment of the Merck China Innovation Cooperation Center (MCICC) on November 1, 2024, aims to enhance collaboration within China's life sciences ecosystem and accelerate the clinical translation of innovative results from China [2] Animal Health - At the expo, Merck also presented its products and solutions covering five major business areas in animal health, including pets, poultry, pigs, ruminants, and aquaculture [2]